MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  

Useful Websites

Global Translations
Medical and Clinical Translation

specialistinfo.com
Details of over 40,000 UK Specialists and over 42,000 GPs

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

Metric Conversions
The Converter Site - unit conversion tool.
home > drug information > Alesse

Alesse (100 mcg levonorgestrel/20 mcg ethinyl estradiol tablets)


Company: Wyeth-Ayerst Laboratories
Approval Status: Approved April 1997
Treatment for: birth control
Areas: Obstetrics/Gynecology

| General Information | Side Effects | Additional Information |


General Information

Other Useful Resources

Alesse (100 mcg levonorgestrel/20 mcg ethinyl estradiol tablets), a new low-dose birth control pill, has been approved for marketing. New Alesse represents the lowest dose combination of levonorgestrel and ethinyl estradiol marketed in the United States. Alesse contains 100 mcg of the progestin levonorgestrel, the most widely prescribed contraceptive progestin, and 20 mcg of ethinyl estradiol, the estrogen most frequently used in oral contraceptives. More than 40 percent of oral contraceptive prescriptions worldwide contain levonorgestrel and ethinyl estradiol. Alesse, packaged in the Mini-Pack, is available in 21- and 28-day regimens. The Mini-Pack, developed by Wyeth-Ayerst, represents the smallest oral contraceptive packaging available. It has several convenient features to help women remember to take their birth control pill daily and in the prescribed sequence.

Alesse, like other oral contraceptive, has proven to be more than 99 percent effective when taken as directed. In addition, birth control pills may provide protection from ovarian and endometrial cancer and pelvic inflammatory disease. They also may make a woman’s period less painful by reducing cramps and increase menstrual cycle regularity. Women who use Alesse or other oral contraceptives may experience iron-deficiency anemia and ectopic pregnancy less frequently.



< back to top

Side Effects

Common side effects associated with oral contraceptives include nausea, headache and breast tenderness. Serious side effects occur infrequently, especially if a woman is in good health and does not smoke. These may include blood clots, heart disease, stroke, liver tumors and gallbladder disease. Several studies have found no overall increase in the risk of developing breast cancer in women taking oral contraceptives. Some women should not use oral contraceptives, including those who have had blood clots, certain cancers, or a history of heart attack or stroke, as well as those who are or may be pregnant.



< back to top

Additional Information

Cigarette smoking increases the risk of serious cardiovascular side effects. This risk increases with age and is most pronounced in women older than age 35. Women on oral contraceptives should not smoke. In addition, oral contraceptives do not protect a woman against HIV infection or other sexually transmitted diseases.



< back to top



The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.




free web search box


pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<




add to google

Add our searches to your Google homepage.

Add to Google

The 60 seconds challenge: Add these searches to your Google homepage within 60 seconds - simply click here and follow these instructions


Receive the latest medical news on your Google homepage.

Add to Google

The 60 seconds challenge: Receive the latest medical news on your Google homepage within 60 seconds - simply click here and follow these instructions





Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, UK Office: +44 (0) 1625 415 347
MediLexicon International Ltd © 2009 All rights reserved.